CEFALY Technology Announces a Collaboration with Genesis Women’s Shelter & Support in Dallas, Texas

Medical device maker CEFALY Technology announced a collaboration with Genesis Women’s Shelter & Support in Dallas, Texas to help domestic violence survivors living with migraine.

As part of its CEFALY Cares initiative, CEFALY Technology has provided Genesis with its innovative migraine treatment and prevention device, as well as educational resources and one-on-one training on migraine management and prevention.

More than 39 million Americans — most of them women — live with migraine, which is a complex and debilitating neurological disorder. Migraine attacks are most commonly characterized by an intense pulsing or throbbing headache on one side of the head, and also may involve other symptoms such as nausea, vomiting, and sensitivity to light and sound.

Migraine and domestic violence are intertwined in multiple ways:

  • Research has shown that people who experience or witness domestic violence in childhood are more likely to develop a headache disorder as adults.
  • In one study, women who had experienced intimate partner violence had increased odds of also having migraine — especially if they also had depression.
  • Stress is the most commonly reported trigger for migraine attacks. The intense stress of an abusive relationship may make migraine worse or increase the frequency of attacks.
  • Leaving an abuser may be more difficult for survivors who live with a chronic illness, such as migraine, if they have been prevented from having independent access to support.
  • Even after a survivor has left an abuser, post-traumatic stress disorder (PTSD) may contribute to migraine.

Jen Trainor McDermott, CEO of CEFALY Technology

“Leaving an abusive relationship and recovering from trauma is hard for anyone — and it can be even more difficult for women living with debilitating migraine pain. CEFALY is proud to partner with Genesis Women’s Shelter & Support to empower the women they serve by providing a drug-free, clinically proven migraine solution that helps them get back to life.”

Genesis is the first women’s shelter receiving a migraine treatment device, training, and education through the CEFALY Cares program. If your organization serves survivors of domestic and sexual violence and would like to participate in CEFALY Cares, please reach out to CEFALY.

About the CEFALY device:

CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain. CEFALY is a non-invasive device placed on the forehead to modify pain sensation in the area research identifies as a center for migraine pain, the trigeminal nerve.

The Bluetooth-enabled CEFALY Connected syncs with the CeCe Migraine Management app and enables users to track CEFALY treatments and log migraine attacks on their mobile device. With these insights, they can better understand their migraine patterns and optimize their treatments.

About Genesis Women’s Shelter & Support:

Genesis Women’s Shelter & Support was founded in 1985 with a goal to not just help women, but to completely eradicate domestic violence. Last year, Genesis served 3,700 women and children at their emergency shelter, transitional housing apartments, and nonresidential offices. Genesis provides services like counseling, legal, advocacy, childcare, occupational therapy and more at no cost and with no strings attached so women know there is help and there is hope.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.